Tempus AI chief accounting officer sells $201,532 in stock

Published 21/02/2025, 01:58
Tempus AI chief accounting officer sells $201,532 in stock

Ryan M. Bartolucci, the Chief Accounting Officer of Tempus AI , Inc. (NASDAQ:TEM), recently sold shares of the company valued at approximately $201,532. The transactions were disclosed in a recent SEC filing. The sale comes as the $14.08 billion market cap company’s stock has seen a 14% decline over the past week, though InvestingPro data shows an impressive 127% gain year-to-date.

On February 19, Bartolucci sold 818 shares of Tempus AI’s Class A Common Stock at prices ranging from $81.83 to $82.36, totaling $66,972. The price per share was calculated as a weighted average, with transactions occurring within the specified range. According to InvestingPro analysis, the stock’s RSI suggests overbought conditions, one of 12 key insights available to subscribers.

The following day, on February 20, Bartolucci sold an additional 1,682 shares at a fixed price of $80 per share, amounting to $134,560. This sale was conducted under a Rule 10b5-1 trading plan, which allows insiders to set up a predetermined plan for trading stocks to avoid any accusations of insider trading.

Following these transactions, Bartolucci holds 44,500 shares of Tempus AI. The sales were made to cover tax withholding obligations related to the vesting of restricted stock units and were not discretionary.

In other recent news, Tempus AI has made significant strides with its recent acquisition of Ambry Genetics, a company with over $300 million in revenue. This strategic move is expected to enhance Tempus AI’s product offerings and market reach, as noted by TD Cowen, which upgraded the stock to a Buy rating and increased the price target to $74. The acquisition positions Tempus AI for improved free cash flow despite Ambry’s slower growth rate. Additionally, the company has launched a new AI-enabled health concierge app named olivia, which aims to centralize patient health data and provide actionable insights. The app is designed to integrate data from over 1,000 health systems and various health devices, offering a comprehensive health management tool for patients. Founder and CEO Eric Lefkofsky highlighted the app’s potential to improve patient outcomes through data and AI. The market has reacted positively to these developments, reflecting investor confidence in Tempus AI’s strategic direction and growth potential.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.